Abstract
Background: The p27Kip1 protein regulates the G1 to S phase transition of cell cycle by binding to and inhibiting the cyclin E/Cdk2 complex. This study explores the prognostic significance of the absence of the p27Kip1 protein in patients with colorectal cancer (CRC).
Methods: Formalin-fixed tumor sections from 124 patients who underwent curative resection for stage I-III CRC were analyzed by immunohistochemistry using MoAb anti-p27Kip1.
Results: Detectable levels of p27Kip1 protein were found in 86% of tumors. Median follow-up was 55 months. Actuarial 5-year disease-free survival (DFS) and overall survival (OS) were 76% and 85%, respectively, in patients with tumors with p27Kip1 protein expression and 34% and 40%, respectively, in those whose tumors lacked p27Kip1 protein expression (P < .001). At multivariate analysis, tumor stage (III vs. I-II) and p27Kip1 protein status (absence vs. presence) were found to be independent prognostic factors for DFS and OS.
Conclusions: Lack of p27Kip1 protein expression in CRC is a negative prognostic marker and may therefore be useful in selecting early-stage patients more likely to benefit from adjuvant treatment.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
REFERENCES
Parker SL, Tong T, Bolden S, et al. Cancer statistics, 1997. CA Cancer J Clin 1997;47:5–27.
NIH Consensus Conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA 1990;264:1444–50.
Moertel CG, Fleming TR, Macdonald JS, et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 1995;122:322–6.
Labianca R, Marsoni S, Pancera G, et al. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet 1995;345:939–44.
Jessup JM, McGinnis LS, Steele GD Jr, et al. Colon cancer: report from the National Cancer Data Base. Cancer 1996;78:918–26.
Willet C, Tepper JE, Cohen AM, Orlow E, Welch C, Donaldson G. Failure patterns following curative resection of colonic carcinoma. Ann Surg 1984;200:685–90.
Mamounas EP, Rockette H, Jones J, et al. Comparative efficacy of adjuvant chemotherapy in patients with Dukes’ B vs. C colon cancer. Results from four NSABP adjuvant studies (E01, E02, E03, E04) [abstract]. Proc Am Soc Clin Oncol 1996;15:205. Abstract 461.
Erlichman C, Marsoni S, Seitz JF, et al. Event free and overall survival is increased by FUFA in resected B colon cancer: a pooled analysis of five randomised trials [abstract]. Proc Am Soc Clin Oncol 1997;16:280. Abstract 991.
Sherr CJ. Cancer cell cycles. Science 1996;274:1672–7.
Polyak K, Lee M-H, Erdjument-Bromage H, et al. Cloning of p27Kip1, a cycline dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 1994;78:59–66.
Porter PL, Malone KE, Heagerty PJ, et al. Expression of cell-cycle regulators p27Kip1 and cycline E, alone and in combination, correlate with survival in young breast cancer patients. Nature Med 1997;3:222–6.
Catzavelos C, Bhattacharya N, Ung YC, et al. Decreased levels of the cell-cycle inhibitor p27Kip1 protein: Prognostic implications in primary breast cancer. Nature Med 1997;3:227–30.
Loda M, Cukor B, Tam SW, et al. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nature Med 1997;3:231–4.
Esposito V, Baldi A, De Luca A, et al. Prognostic role of the cycline-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res 1997;57:3381–5.
UICC. TNM atlas: illustrated guide to the TNM/pTNM classification of malignant tumor. Berlin: Springer-Verlag, 1992.
Morson BC, Sobin LH. Histologic typing of intestinal tumors: WHO technical report No. 15. Geneva: World Health Organization, 1976.
Kaplan EL, Meier P. Nonparametrics estimation from incomplete observations. J Am Stat Assoc 1958;53:457–81.
Cox DR. Regression models and life tables. J R Stat Soc (B) 1972;34:187–220.
Ciaparrone M, Yamamoto H, Yao Y, et al. Localization and expression of p27Kip1 in multistage colorectal carcinogenesis. Cancer Res 1998;114–22.
Fredersdorf S, Burns J, Milne AM, et al. High level expression of p27Kip1 and cycline D1 in some human breast cancer cells: inverse correlation between the expression of p27Kip1 and degree of malignancy in human breast and colorectal cancers. Proc Natl Acad Sci USA 1997;94:6380–5.
Kawamata N, Morosetti R, Miller CW, et al. Molecular analysis of the cyclin-dependent kinase inhibitor gene p27/Kip1 in human malignancies. Cancer Res 1995;55:2266–9.
Pagano M, Tam SW, Theodoras AM, et al. Role of the ubiquitinproteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 1995;269:682–5.
Hengst L, Reed SI. Translational control of p27Kip1 accumulation during the cell cycle. Science 1996;271:1861–4.
Fielding LP, Pettigrew N. College of American Pathologists Conference XXVI on clinical relevance of prognostic markers in solid tumors. Report of the colorectal cancer working group. Arch Pathol Lab Med 1995;119:1115–21.
Craig C, Wersto R, Kim M, et al. A recombinant adenovirus expressing p27Kip1 induces cell cycle arrest and loss of cycline-Cdk activity in human breast cancer cells. Oncogene 1997;14:2283–9.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Belluco, C., Esposito, G., Bertorelle, R. et al. Absence of the Cell Cycle Inhibitor p27Kip1 Protein Predicts Poor Outcome in Patients With Stage I-III Colorectal Cancer. Ann Surg Oncol 6, 19–25 (1999). https://doi.org/10.1007/s10434-999-0019-2
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s10434-999-0019-2